CANNABIS SCIENCE - Revolution oder Verblendung ?

ich habe das schon öfters bei vielen Aktien erlebt. Immer wenn eine Aktie sich den Boden nähert, wird mit einem Schlag alles an Aktien aufgekauft. Das sind meist anonyme Groß- und einflussreiche Privatinvestoren. Alleine der gewaltige Anstieg reicht dann schon für eine Meldung, die dann durchs Netz rast.

Der Hype lag also am Hype selbst. -> Geld zieht Geld.

Ich hatte hier vor einiger Zeit geschrieben und auch erklärt, weshalb es Routineabzocke ist, aber den Kommentar hat man entfernen lassen.

Der Kurs selbst ging die ganze Zeit so steil herunter, weil irgendeiner eine extrem große Order ganz unten gesetzt hatte. Der Marketmaker sucht sich bekanntlich den Kurs, bei dem die meisten Stückzahlen gehandelt werden. So führt Eins zum Anderen.


Ich glaube aber, dass es sich auf lange Sicht hin lohnt, hier zu investieren. Beachten sollte man aber auch, dass diese Firma noch viel Kapital benötigen wird.  

geht wieder was  

Innerhalb weniger Minuten von 0.0275 auf 0.025.  

billig rein  

 

Cannabis Science to Begin Its Drug Development Program With IGXBio and Its GenePro(R), DNA-Based Immunotherapeudic, FDA IND # Approved
WASHINGTON, DC -- (Marketwired) -- 11/02/15 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicine, has announced a significant collaborative drug development deal with IGXBio Inc., and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies will develop joint protocols that explore potential synergistic effects of their respective drug candidates, as well as potential new drug candidate opportunities.

"After recent discussions with Mr. Jim Laufenberg, President of IGXbio Inc., and Dr. Allen Herman, Chief Medical Officer, Cannabis Science Inc., we have decided it's time to accelerate our collaborative drug development program. Dr. Herman will work closely with Mr. Laufenberg to choose the team of scientists responsible for the integrity of the research, define laboratory requirements for each stage of development, and delineate the shared scope of work between CBIS and IGXBio. Jim and I are on the final joint steering committee to ensure our project is committed, fired up, and underway," said Mr. Raymond C. Dabney, President and CEO of CBIS.

IGXBio has a drug called GenePro®, which is already registered with the FDA and has an IND number. This expedites the process to seek FDA approval in the future. GenePro® is designed to promote an anti-HIV immune response that facilitates virus control in HIV-infected subjects. There are more than 150 peer-reviewed publications that describe the effectiveness of GenePro®. The inflammatory response that is associated with HIV infection is present at even low levels of viral replication, and is a major causal factor for the morbidities and associated mortality of HIV infection. Low-grade inflammation frequently occurs despite clinically successful anti-retroviral therapy and is associated with increased incidence of heart disease, bone disease, and cancers.

"If inflammation can be minimized or eliminated along with HIV viral replication it will improve the health and extend the lives of HIV-positive people. By partnering CS-TATI-1 and GenePro® we believe this is possible. Our collaboration is designed to provide novel insights into the role of inflammation in HIV disease and we hope to provide critical pharmaceutical resources for optimizing effective treatments for AIDS patients in various resource settings. The drug development program is designed to demonstrate the enhanced potential of therapeutic vaccination and the anti-inflammatory effects of cannabinoids to deter disease progression in AIDS patients unable to achieve control HIV replication," stated Allen A. Herman, M.B., Ch.B., Ph.D.


Link: http://www.finanznachrichten.de/...erapeudic-fda-ind-approved-256.htm  

Cannabis-Aktien die größtenteils Cannabis für das kiffen produzieren?

Was man da so liest machen die einiges an  Umsatz.

 

...dass der Kurs bei solch einem Volumen nicht deutlich ansteigt. Wollen wohl noch Einige raus aus dem Wert.  

War doch 17% im Plus?

 

hatte es nicht mehr verfolgt.  

warum Divi? was soll den das für eine Divi sein? bei dem Wert.

0,0001?  

http://www.finanznachrichten.de/...orate-and-product-branding-256.htm  

Es gibt ständig News und das Volumen ist anhaltend hoch. Der Kurs kommt aber nicht aus dem Knick.  

versteh ich auch gar nicht es gibt ständig News und das Ding geht mehr runter wie hoch.
bei uns wird auch gekauf die Umsätze sind nicht schlecht für so ein Penny.
irgendwann muss es hoch gehen  

http://ih.advfn.com/p.php?pid=nmona&article=69437715  

Cannabis Science Releases Cannabinoid-Formulated Capsule Product Line in California; Initial Capsule Formulations Released Are CBD, Indica, and Sativa
COLORADO SPRINGS, CO -- (Marketwired) -- 11/30/15 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based formulation, announces the launch of their cannabinoid-formulated capsule product line. The initial capsule formulations released are CBD, Indica, and Sativa; each of the three types of caps will be available in 25mg, 50mg, and 100mg doses and will be provided in two-dose packs with more size options to be made available in the near future.

"We are very excited to get our next line of Cannabis Science Brand Products on the market. The Capsules are important because of the popularity and ease of the delivery mechanism. The Company reps have already begun distributing to a number of dispensaries throughout California. They anticipate the Caps to be in a much larger number of dispensaries, and look forward to being able to line the shelves with a full lineup of Cannabis Science Brand Health-Related Products. Debuting the Caps at the Emerald Cup will be very interesting for us, with this being our first actual product contest," stated Cannabis Science, Inc. President & CEO, Co-Founder, Raymond C. Dabney.

Just in time for the Emerald Cup event in Santa Rosa, California, on December 12th and 13th, 2015. Cannabis Science will be prepared to debut their new, high potency CBD, Indica, and Sativa capsules at the event. The capsules or "caps" are expected be used for self-medicating applications ranging from pain and inflammation reduction to neurological treatments. The Emerald Cup event is expected to expose Cannabis Science's new products to a wide audience immediately, which will help the company build brand equity in this relatively new market.

Mr. Dabney concludes, "It has certainly been a long road to get here, but we are here no doubt. To see things coming together as they are, is very exciting for us of course. With the dividend almost completed, more new products being released, preparations for the larger capital raise, progressing our formal FDA drug development initiatives and proposed NASDAQ uplisting, things are certainly on the move, in the right direction. On the dividend, we have submitted some additional requested documentation to FINRA; we hope this to be the last and then we can begin the dividend share distribution and proceed to file for a new additional trading symbol to accommodate the much larger capital raise."

Link: http://www.finanznachrichten.de/...-are-cbd-indica-and-sativa-256.htm  

heute mal nachgekauft. Mal gucken wo die Reise hin geht  

da müssen Hammer News her sonnst geht da gar nichts....  

Ich persönlich glaube an das grüne Gold und sehe rosige Zeiten. Ob da Cannabis Science dabei ist ?? Hoffentlich :).

Welche Cannabis Aktien habt ihr den noch.? Wollte mal bei CannaVest einsteigen aber die ist auch nur noch am fallen.

 

Das „grüne Gold“ für Heimtiere, finde ist ne gute Ergänzung zu Cannabis Science ;-)  

ich heute auch nachgekauft.  

Cannabis Aktien gehen down!  

Cannabis Science Releases Forward-Looking Clinical Guidance for 2016; the Company Is Positioned to Expand Clinical Trials Into the New Year

COLORADO SPRINGS, CO -- (Marketwired) -- 01/05/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to release forward-looking guidance for 2016. With the pharmaceutical industry in closely targeted sights, Cannabis Science has started the new year healthier than any year prior.

The Company has placed heavy emphasis to accelerate its pharmaceutical drug development programs, as the industry is expected to reach $1.2 trillion globally by 2018. The Company's main goal here is to acquire national and international regulatory approval for its cannabis-based formulations, subsequently giving the Company substantial revenue growth considerations. The Company is focused on three main formal drug targets, proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Further to its expanded pharmaceutical drug development program with partner ImmunoClin (IMCL) out of Europe. The fully GMP compliant facilities are licensed and the Company is already working in the lab to realistically accomplish its aggressive goals. The expanded program is focused on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe.

In the State of California, Cannabis Science is seeing great success with initial production and testing of its Pure Decarboxylated CO2 Oil (PDCO) and CBD, Sativa, and Indica Capsule products during the last quarter of 2015. The capsules were debuted at The Emerald Cup, a cannabis-centric event attended by over 20,000 consumers and industry vendors. In 2016, product improvements will continue to be made and these products will be rolled out to a wider array of dispensaries. Marketing efforts for the capsule products will be ramped up in 2016, as the company's products are now completely viable and have received outstanding feedback from consumers to date.

To further cement its foothold in the substantial pharmaceutical drug development industry, the Company expects its IGXBIO, Genepro drug development program to be a major pharmaceutical win. Program specific details are expected to be announced in early 2016.

"2015 was a great year of growth for our Company. We made a great deal of progress with our drug development, acquisition strategy, product roll out, and strategic partnership search," said company Director, President, Co-Founder & CEO, Raymond C. Dabney. "With that said, 2016 is looking to be an exciting year for Cannabis Science. We are kicking off the new year with new products already brought to market -- a huge head start over last year. We look forward to announcing all of our ground-breaking progress, step by step, along the way."

Link: http://www.finanznachrichten.de/...l-trials-into-the-new-year-256.htm  

deutsch?  

Cannabis Science Announces Update on Issuance of Dividends / The Company Continues Open Dialogue With FINRA and Remains Diligent as Issuance Passes Through Regulatory Process to Finalization
COLORADO SPRINGS, CO -- (Marketwired) -- 01/11/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced an update on its dividend process. The Company is actively working with FINRA for final approval of the two pending dividends issued to shareholders of record on each respective date (December 31, 2010 and October 9, 2015).

Company counsel continues to answer inquiries from FINRA as they arise. The regulatory process is moving forward, and the Company is doing everything it can to expedite the process.

"We are working as hard as we can on the dividend issuance regulatory process. We are working actively with FINRA and will provide updates as they become available. We are very motivated to get these dividends out to our wonderful shareholders not only because their issuance can work as a trigger to the Company's financial benefit, but also because dividends provide a well- deserved reward to our shareholders," said Director, President, Co-Founder & CEO Raymond C. Dabney. "We are happy to see significant progress being made."

As a recap, the following is the criteria for each respective dividend:

(1) To issue a new dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 100 shares of our current class of common stock that they previously owned as of the record date, October 9, 2015. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol.

(2) To issue the previously announced and approved dividend that will issue 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the Company's current common stock that they previously owned as of the record date of December 31, 2010. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol.

Cannabis Science's investor relations department has been receiving a great deal of call volume regarding the dividend process. Updates will be provided as progress is made, and the Company remains excited and motivated to finish the issuance process.

Link: http://www.finanznachrichten.de/...igent-as-issuance-passes-t-256.htm